APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non Hodgkin Lymphoma (NHL)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Non Hodgkin Lymphoma (NHL) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025181 pages

Choose your research edition.

Industry ResearchNon Hodgkin Lymphoma (NHL) Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Non Hodgkin Lymphoma (NHL) Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Non Hodgkin Lymphoma (NHL) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non Hodgkin Lymphoma (NHL) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Non Hodgkin Lymphoma (NHL) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Non Hodgkin Lymphoma (NHL) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Non Hodgkin Lymphoma (NHL) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non Hodgkin Lymphoma (NHL) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non Hodgkin Lymphoma (NHL) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Non Hodgkin Lymphoma (NHL) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Non Hodgkin Lymphoma (NHL) include Bristol Myers Squibb, Celgene, F. Hoffmann-La Roche, Bayer, GlaxoSmithKline, Eli Lilly, Merck and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Non Hodgkin Lymphoma (NHL) market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non Hodgkin Lymphoma (NHL) and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non Hodgkin Lymphoma (NHL) revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Non Hodgkin Lymphoma (NHL) market size, projected growth trends, production technologies, key applications, and end-use industries.

Non Hodgkin Lymphoma (NHL) Segment by Company

Bristol Myers Squibb

Celgene

F. Hoffmann-La Roche

Bayer

GlaxoSmithKline

Eli Lilly

Merck

Johnson & Johnson

Non Hodgkin Lymphoma (NHL) Segment by Type

Standard

Exellent

Non Hodgkin Lymphoma (NHL) Segment by Application

Hosptial

Clinic

Non Hodgkin Lymphoma (NHL) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non Hodgkin Lymphoma (NHL) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non Hodgkin Lymphoma (NHL) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non Hodgkin Lymphoma (NHL).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Non Hodgkin Lymphoma (NHL) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non Hodgkin Lymphoma (NHL) industry.

Chapter 3: Detailed analysis of Non Hodgkin Lymphoma (NHL) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non Hodgkin Lymphoma (NHL)revenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Standard Table 3. Key Players of Exellent Table 4. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hosptial Table 6. Key Players of Clinic Table 7. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2021-2026) & (US$ Million) Table 9. Global Non Hodgkin Lymphoma (NHL) Market Share by Region (2021-2026) Table 10. Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2027-2032) & (US$ Million) Table 11. Global Non Hodgkin Lymphoma (NHL) Market Share by Region (2027-2032) Table 12. Non Hodgkin Lymphoma (NHL) Industry Trends Table 13. Non Hodgkin Lymphoma (NHL) Industry Drivers Table 14. Non Hodgkin Lymphoma (NHL) Industry Opportunities and Challenges Table 15. Non Hodgkin Lymphoma (NHL) Industry Restraints Table 16. Global Non Hodgkin Lymphoma (NHL) Revenue by Company (US$ Million) & (2021-2026) Table 17. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Company (2021-2026) Table 18. Global Non Hodgkin Lymphoma (NHL) Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global Non Hodgkin Lymphoma (NHL) Key Company Head Office and Area Served Table 20. Global Non Hodgkin Lymphoma (NHL) Company, Product Type & Application Table 21. Global Non Hodgkin Lymphoma (NHL) Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global Non Hodgkin Lymphoma (NHL) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global Non Hodgkin Lymphoma (NHL) Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026) & (US$ Million) Table 26. Global Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032) & (US$ Million) Table 27. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2021-2026) Table 28. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2027-2032) Table 29. Global Non Hodgkin Lymphoma (NHL) Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026) & (US$ Million) Table 31. Global Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032) & (US$ Million) Table 32. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2021-2026) Table 33. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2027-2032) Table 34. Bristol Myers Squibb Company Information Table 35. Bristol Myers Squibb Business Overview Table 36. Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Product Portfolio Table 38. Bristol Myers Squibb Recent Development Table 39. Celgene Company Information Table 40. Celgene Business Overview Table 41. Celgene Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Celgene Non Hodgkin Lymphoma (NHL) Product Portfolio Table 43. Celgene Recent Development Table 44. F. Hoffmann-La Roche Company Information Table 45. F. Hoffmann-La Roche Business Overview Table 46. F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Product Portfolio Table 48. F. Hoffmann-La Roche Recent Development Table 49. Bayer Company Information Table 50. Bayer Business Overview Table 51. Bayer Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Bayer Non Hodgkin Lymphoma (NHL) Product Portfolio Table 53. Bayer Recent Development Table 54. GlaxoSmithKline Company Information Table 55. GlaxoSmithKline Business Overview Table 56. GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Product Portfolio Table 58. GlaxoSmithKline Recent Development Table 59. Eli Lilly Company Information Table 60. Eli Lilly Business Overview Table 61. Eli Lilly Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Eli Lilly Non Hodgkin Lymphoma (NHL) Product Portfolio Table 63. Eli Lilly Recent Development Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Merck Non Hodgkin Lymphoma (NHL) Product Portfolio Table 68. Merck Recent Development Table 69. Johnson & Johnson Company Information Table 70. Johnson & Johnson Business Overview Table 71. Johnson & Johnson Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Johnson & Johnson Non Hodgkin Lymphoma (NHL) Product Portfolio Table 73. Johnson & Johnson Recent Development Table 74. North America Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026) & (US$ Million) Table 75. North America Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032) & (US$ Million) Table 76. North America Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026) & (US$ Million) Table 77. North America Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032) & (US$ Million) Table 78. North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026) Table 80. North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2027-2032) Table 81. Europe Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026) & (US$ Million) Table 82. Europe Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032) & (US$ Million) Table 83. Europe Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026) & (US$ Million) Table 84. Europe Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032) & (US$ Million) Table 85. Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026) Table 87. Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2027-2032) Table 88. China Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026) & (US$ Million) Table 89. China Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032) & (US$ Million) Table 90. China Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026) & (US$ Million) Table 91. China Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032) & (US$ Million) Table 92. Asia Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026) & (US$ Million) Table 93. Asia Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032) & (US$ Million) Table 94. Asia Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026) & (US$ Million) Table 95. Asia Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032) & (US$ Million) Table 96. Asia Non Hodgkin Lymphoma (NHL) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Asia Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026) Table 98. Asia Non Hodgkin Lymphoma (NHL) Market Size by Country (2027-2032) Table 99. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026) & (US$ Million) Table 100. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032) & (US$ Million) Table 101. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026) & (US$ Million) Table 102. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032) & (US$ Million) Table 103. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026) Table 105. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2027-2032) Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Non Hodgkin Lymphoma (NHL) Product Image Figure 2. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Non Hodgkin Lymphoma (NHL) Market Share by Type: 2025 VS 2032 Figure 4. Standard Image Figure 5. Exellent Image Figure 6. Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Non Hodgkin Lymphoma (NHL) Market Share by Application: 2025 VS 2032 Figure 8. Hosptial Image Figure 9. Clinic Image Figure 10. Global Non Hodgkin Lymphoma (NHL) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 12. Global Non Hodgkin Lymphoma (NHL) Market Share by Region: 2025 VS 2032 Figure 13. Years Considered Figure 14. Global Non Hodgkin Lymphoma (NHL) Market Share by Players in 2025 Figure 15. Global Top 5 and 10 Non Hodgkin Lymphoma (NHL) Players Market Share by Revenue in 2025 Figure 16. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Non Hodgkin Lymphoma (NHL) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Type (2021-2032) Figure 19. Global Non Hodgkin Lymphoma (NHL) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Non Hodgkin Lymphoma (NHL) Revenue Market Share by Application (2021-2032) Figure 21. North America Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 22. North America Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032) Figure 23. North America Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032) Figure 24. North America Non Hodgkin Lymphoma (NHL) Market Share by Country (2021-2032) Figure 25. United States Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 26. Canada Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 27. Mexico Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 28. Europe Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 29. Europe Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032) Figure 30. Europe Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032) Figure 31. Europe Non Hodgkin Lymphoma (NHL) Market Share by Country (2021-2032) Figure 32. Germany Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 33. France Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 34. U.K. Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 35. Italy Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 36. Russia Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 37. Nordic Countries Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 38. China Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 39. China Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032) Figure 40. China Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032) Figure 41. Asia Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 42. Asia Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032) Figure 43. Asia Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032) Figure 44. Asia Non Hodgkin Lymphoma (NHL) Market Share by Country (2021-2032) Figure 45. Japan Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 46. South Korea Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 47. Taiwan Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 48. Southeast Asia Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 49. India Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 50. Australia Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 51. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032) Figure 53. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032) Figure 54. South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Country (2021-2032) Figure 55. Brazil Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 56. South Africa Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 58. Turkey Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 59. Argentina Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 60. UAE Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 61. Egypt Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 62. Chile Non Hodgkin Lymphoma (NHL) Market Size (2021-2032) & (US$ Million) Figure 63. Research Process Figure 64. Key Executives Interviewed

Scope & coverage.

Types
  • Standard
  • Exellent
Applications
  • Hosptial
  • Clinic
Companies covered
  • Bristol Myers Squibb
  • Celgene
  • F. Hoffmann-La Roche
  • Bayer
  • GlaxoSmithKline
  • Eli Lilly
  • Merck
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Standard
  5. 1.2.3 Exellent
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Non Hodgkin Lymphoma (NHL) Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Hosptial
  9. 1.3.3 Clinic
  10. 1.4 Global Market Growth Prospects
  11. 1.5 Global Non Hodgkin Lymphoma (NHL) Growth Trends by Region
  12. 1.5.1 Global Non Hodgkin Lymphoma (NHL) Market Size by Region: 2021 VS 2025 VS 2032
  13. 1.5.2 Non Hodgkin Lymphoma (NHL) Market Size by Region (2021-2026)
  14. 1.5.3 Non Hodgkin Lymphoma (NHL) Market Size by Region (2027-2032)
  15. 1.6 Assumptions and Limitations
  16. 1.7 Study Goals and Objectives
  17. 1.8 Years Considered
2 Global Non Hodgkin Lymphoma (NHL) Market Dynamics
  1. 2.1 Non Hodgkin Lymphoma (NHL) Industry Trends
  2. 2.2 Non Hodgkin Lymphoma (NHL) Industry Drivers
  3. 2.3 Non Hodgkin Lymphoma (NHL) Industry Opportunities and Challenges
  4. 2.4 Non Hodgkin Lymphoma (NHL) Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Non Hodgkin Lymphoma (NHL) Revenue by Company (2021-2026)
  2. 3.2 Global Non Hodgkin Lymphoma (NHL) Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Non Hodgkin Lymphoma (NHL) Key Company Head office and Area Served
  4. 3.4 Global Non Hodgkin Lymphoma (NHL) Company, Product Type & Application
  5. 3.5 Global Non Hodgkin Lymphoma (NHL) Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Non Hodgkin Lymphoma (NHL) Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Non Hodgkin Lymphoma (NHL) Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Non Hodgkin Lymphoma (NHL) Tier 1, Tier 2, and Tier 3
4 Non Hodgkin Lymphoma (NHL) Market by Type
  1. 4.1 Global Non Hodgkin Lymphoma (NHL) Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2032)
  3. 4.3 Global Non Hodgkin Lymphoma (NHL) Market Size Share by Type (2021-2032)
5 Non Hodgkin Lymphoma (NHL) Market by Application
  1. 5.1 Global Non Hodgkin Lymphoma (NHL) Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2032)
  3. 5.3 Global Non Hodgkin Lymphoma (NHL) Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Bristol Myers Squibb
  2. 6.1.1 Bristol Myers Squibb Company Information
  3. 6.1.2 Bristol Myers Squibb Business Overview
  4. 6.1.3 Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Product Portfolio
  6. 6.1.5 Bristol Myers Squibb Recent Developments
  7. 6.2 Celgene
  8. 6.2.1 Celgene Company Information
  9. 6.2.2 Celgene Business Overview
  10. 6.2.3 Celgene Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Celgene Non Hodgkin Lymphoma (NHL) Product Portfolio
  12. 6.2.5 Celgene Recent Developments
  13. 6.3 F. Hoffmann-La Roche
  14. 6.3.1 F. Hoffmann-La Roche Company Information
  15. 6.3.2 F. Hoffmann-La Roche Business Overview
  16. 6.3.3 F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Product Portfolio
  18. 6.3.5 F. Hoffmann-La Roche Recent Developments
  19. 6.4 Bayer
  20. 6.4.1 Bayer Company Information
  21. 6.4.2 Bayer Business Overview
  22. 6.4.3 Bayer Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Bayer Non Hodgkin Lymphoma (NHL) Product Portfolio
  24. 6.4.5 Bayer Recent Developments
  25. 6.5 GlaxoSmithKline
  26. 6.5.1 GlaxoSmithKline Company Information
  27. 6.5.2 GlaxoSmithKline Business Overview
  28. 6.5.3 GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Product Portfolio
  30. 6.5.5 GlaxoSmithKline Recent Developments
  31. 6.6 Eli Lilly
  32. 6.6.1 Eli Lilly Company Information
  33. 6.6.2 Eli Lilly Business Overview
  34. 6.6.3 Eli Lilly Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Eli Lilly Non Hodgkin Lymphoma (NHL) Product Portfolio
  36. 6.6.5 Eli Lilly Recent Developments
  37. 6.7 Merck
  38. 6.7.1 Merck Company Information
  39. 6.7.2 Merck Business Overview
  40. 6.7.3 Merck Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Merck Non Hodgkin Lymphoma (NHL) Product Portfolio
  42. 6.7.5 Merck Recent Developments
  43. 6.8 Johnson & Johnson
  44. 6.8.1 Johnson & Johnson Company Information
  45. 6.8.2 Johnson & Johnson Business Overview
  46. 6.8.3 Johnson & Johnson Non Hodgkin Lymphoma (NHL) Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Johnson & Johnson Non Hodgkin Lymphoma (NHL) Product Portfolio
  48. 6.8.5 Johnson & Johnson Recent Developments
7 North America
  1. 7.1 North America Non Hodgkin Lymphoma (NHL) Market Size (2021-2032)
  2. 7.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Type
  3. 7.2.1 North America Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026)
  4. 7.2.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032)
  5. 7.2.3 North America Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032)
  6. 7.3 North America Non Hodgkin Lymphoma (NHL) Market Size by Application
  7. 7.3.1 North America Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026)
  8. 7.3.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032)
  9. 7.3.3 North America Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032)
  10. 7.4 North America Non Hodgkin Lymphoma (NHL) Market Size by Country
  11. 7.4.1 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026)
  13. 7.4.3 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2027-2032)
  14. 7.4.4 North America Non Hodgkin Lymphoma (NHL) Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Non Hodgkin Lymphoma (NHL) Market Size (2021-2032)
  2. 8.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Type
  3. 8.2.1 Europe Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026)
  4. 8.2.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032)
  5. 8.2.3 Europe Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032)
  6. 8.3 Europe Non Hodgkin Lymphoma (NHL) Market Size by Application
  7. 8.3.1 Europe Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026)
  8. 8.3.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032)
  9. 8.3.3 Europe Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032)
  10. 8.4 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country
  11. 8.4.1 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026)
  13. 8.4.3 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2027-2032)
  14. 8.4.4 Europe Non Hodgkin Lymphoma (NHL) Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Non Hodgkin Lymphoma (NHL) Market Size (2021-2032)
  2. 9.2 China Non Hodgkin Lymphoma (NHL) Market Size by Type
  3. 9.2.1 China Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026)
  4. 9.2.2 China Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032)
  5. 9.2.3 China Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032)
  6. 9.3 China Non Hodgkin Lymphoma (NHL) Market Size by Application
  7. 9.3.1 China Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026)
  8. 9.3.2 China Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032)
  9. 9.3.3 China Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Non Hodgkin Lymphoma (NHL) Market Size (2021-2032)
  2. 10.2 Asia Non Hodgkin Lymphoma (NHL) Market Size by Type
  3. 10.2.1 Asia Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026)
  4. 10.2.2 Asia Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032)
  5. 10.2.3 Asia Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032)
  6. 10.3 Asia Non Hodgkin Lymphoma (NHL) Market Size by Application
  7. 10.3.1 Asia Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026)
  8. 10.3.2 Asia Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032)
  9. 10.3.3 Asia Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032)
  10. 10.4 Asia Non Hodgkin Lymphoma (NHL) Market Size by Country
  11. 10.4.1 Asia Non Hodgkin Lymphoma (NHL) Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026)
  13. 10.4.3 Asia Non Hodgkin Lymphoma (NHL) Market Size by Country (2027-2032)
  14. 10.4.4 Asia Non Hodgkin Lymphoma (NHL) Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst